menu
    • menu
    [{"orgOrder":0,"company":"OncXerna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Navicixizumab","moa":"||monoclonal antibodies: combination of humanized and chimeric chains","graph1":"Oncology","graph2":"Phase III","graph3":"OncXerna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncXerna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OncXerna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OncXerna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Navicixizumab","moa":"||monoclonal antibodies: combination of humanized and chimeric chains","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncXerna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"OncXerna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"OncXerna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Oncologie","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Navicixizumab","moa":"monoclonal antibodies: combination of humanized and chimeric chains","graph1":"Oncology","graph2":"Phase I","graph3":"Mereo BioPharma Group","amount2":0.31,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.31,"dosageForm":"Intravenous Infusion","sponsorNew":"Mereo BioPharma Group \/ Oncologie","highestDevelopmentStatusID":"6","companyTruncated":"Mereo BioPharma Group \/ Oncologie"},{"orgOrder":0,"company":"Qiagen","sponsor":"OncXerna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"Navicixizumab","moa":"monoclonal antibodies: combination of humanized and chimeric chains","graph1":"Oncology","graph2":"Phase I","graph3":"Qiagen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Qiagen \/ OncXerna Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Qiagen \/ OncXerna Therapeutics"},{"orgOrder":0,"company":"OncXerna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Navicixizumab","moa":"monoclonal antibodies: combination of humanized and chimeric chains","graph1":"Oncology","graph2":"Phase III","graph3":"OncXerna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncXerna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"OncXerna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OncXerna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Navicixizumab","moa":"monoclonal antibodies: combination of humanized and chimeric chains","graph1":"Oncology","graph2":"Phase II","graph3":"OncXerna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncXerna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OncXerna Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Navicixizumab

    Menu

    Navicixizumab

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            OncXerna Therapeutics

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            OncXerna Therapeutics

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Navicixizumab,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            OncXerna Therapeutics Doses First Patient in Phase 2 Trial Evaluating Navicixizumab Alone or in Combination wi...

                            Details : Navicixizumab is an anti-DLL4/VEGF bispecific antibody product candidate that demonstrated antitumor activity in patients who were previously treated with Avastin® (bevacizumab) in a Phase 1b clinical trial.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            August 09, 2022

                            Lead Product(s) : Navicixizumab,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            OncXerna Therapeutics

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            OncXerna Therapeutics

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Navicixizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            July 12, 2022

                            Lead Product(s) : Navicixizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            OncXerna Therapeutics

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            OncXerna Therapeutics

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Navicixizumab,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            OncXerna Therapeutics Announces Journal of Clinical Oncology Publication Featuring Phase 1b Data of Navicixizu...

                            Details : Overall response rate (ORR) of 43% and median duration of response of 6 months seen with an anti-DLL4/VEGF bispecific antibody, navicixizumab in combination with paclitaxel heavily pretreated platinum-resistant ovarian cancer patients.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            April 21, 2022

                            Lead Product(s) : Navicixizumab,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            OncXerna Therapeutics

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            OncXerna Therapeutics

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Navicixizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            September 14, 2021

                            Lead Product(s) : Navicixizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Qiagen

                            Germany arrow
                            ChemOutsourcing
                            Not Confirmed

                            Qiagen

                            Germany arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Navicixizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : OncXerna Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            QIAGEN and OncXerna Therapeutics Sign Diagnostic Agreements

                            Details : QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna™ TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            September 08, 2021

                            Lead Product(s) : Navicixizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : OncXerna Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Mereo BioPharma Group

                            United Kingdom arrow
                            ChemOutsourcing
                            Not Confirmed

                            Mereo BioPharma Group

                            United Kingdom arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Navicixizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Oncologie

                            Deal Size : $306.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab

                            Details : Under the terms and conditions of the agreement, Oncologie receives exclusive global license to develop and commercialize navicixizumab.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : $4.0 million

                            January 13, 2020

                            Lead Product(s) : Navicixizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Oncologie

                            Deal Size : $306.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth